TAKEDA PHARMACEUTICAL CO LTD (TAK) Stock
TAK has an Alpha Score of 40 out of 100 (weak), computed on Nov 6, 2026 from 3 of 4 sub-scores. 4 members of Congress disclosed 7 trades in TAK since 2018: 4 purchases and 3 sales, most recently Virginia Foxx (sale, Aug 29, 2023). 6 of the hedge funds AlphaScala tracks reported TAK in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $41.17M. Company insiders reported 0 open-market buys and 22 sales on SEC Form 4 in the 90 days to Nov 5, 2026. Its trailing P/E ratio is 260.2 and its net margin 0.9% (key statistics as of Nov 3, 2026).
What is TAK's Alpha Score?
How it works →Alpha Score of 40 reflects weak overall profile with moderate momentum, weak value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded TAKEDA PHARMACEUTICAL CO LTD (TAK)?
Most recent: Virginia Foxx (sale, Aug 29, 2023); records start Dec 21, 2018.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Virginia Foxx R-NC · House | 2023-08-29 | sale | $15k – $50k |
| Dan Goldman D-NY · House | 2023-07-10 | sale | $15k – $50k |
| Dan Goldman D-NY · House | 2023-02-27 | purchase | $1k – $15k |
| Virginia Foxx R-NC · House | 2023-02-16 | purchase | $1k – $15k |
| Virginia Foxx R-NC · House | 2022-11-01 | purchase | $1k – $15k |
| Van Taylor R-TX · House | 2019-03-25 | sale | $15k – $50k |
| Greg Gianforte R-MT · House | 2018-12-21 | purchase | $15k – $50k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all TAK political trades →Which hedge funds own TAK?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 2.57M | $41.17M | -14% |
| D.E. Shaw David Shaw | 2.05M | $32.85M | -21% |
| Millennium Management Israel Englander | 1.05M | $16.84M | NEW |
| Citadel Ken Griffin | 168K | $2.70M | -73% |
| Point72 Steve Cohen | 78K | $1.24M | NEW |
| Marshall Wace | 18K | $288.5K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are TAKEDA PHARMACEUTICAL CO LTD insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 4, 26 | Platford Giles Richard | President, IBU | SELL | 55.6K | $1.2M |
| Nov 2, 26 | Bitetti Teresa Marie | President, OBU | SELL | 46.6K | $974K |
| Sep 14, 26 | Duprey Lauren Rusckowski | Chief Transformation Officer | SELL | 34.5K | $640K |
| Sep 2, 26 | Plump Andrew Stewart | President, R&D | SELL | 116.2K | $2.1M |
| Aug 19, 26 | Plump Andrew Stewart | President, R&D | SELL | 19.7K | $363K |
| Aug 18, 26 | Greenway Nicola Deidre Petal | Chief Human Resources Officer | SELL | 13.0K | $235K |
| Aug 11, 26 | Shannon Elaine Mary | Pres., Global Supply & Quality | SELL | 20.4K | $357K |
| Aug 10, 26 | Greenway Nicola Deidre Petal | Chief Human Resources Officer | SELL | 975 | $17K |
| Aug 10, 26 | Greenway Nicola Deidre Petal | Chief Human Resources Officer | SELL | 33.6K | $589K |
| Aug 10, 26 | Furney Natalie Anne Marie | Global General Counsel | SELL | 30.9K | $528K |
SEC Form 4 filings as of Nov 5, 2026
See cluster-buy signals across all tickers →What are TAK's key statistics?
Key statistics as of Nov 3, 2026
How does TAK's valuation compare with the Healthcare sector?
| Metric | TAK | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 260.2 | 28.7 | 108 |
| Net margin | 0.87% | 4.11% | 160 |
| Return on equity | 0.54% | 5.18% | 180 |
| Dividend yield (payers) | 4.41% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 6, 2026). P/E excludes loss-making companies.
TAK price chart
Powered by TradingViewWhat does TAKEDA PHARMACEUTICAL CO LTD do?
Takeda Pharmaceutical Company Limited American Depositary Receipt represents ownership in Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company. It provides international investors access to the company's ordinary shares, with a ratio of 2 ADSs equaling 1 ordinary share, facilitating dividends converted from Japanese Yen to US Dollars by the depositary bank. The company focuses on researching, developing, manufacturing, and marketing pharmaceutical drugs across five core therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which form the majority of its business. Its operations span diverse geographies, including significant presence in the US, Japan, Europe, and Canada, serving global healthcare needs through innovative treatments. Founded in 1781 and headquartered in Tokyo, Japan, Takeda Pharmaceutical Company Limited maintains a strong emphasis on capital allocation for growth and shareholder returns while upholding investment-grade credit ratings.